Most follow-up extends 12–24 months; longer data are rare. Some patients report stable scores for 2–3 years, others progress. Progressive forms show variable trajectories with few patients studied. Any effect likely reflects temporary immune modulation rather than permanent remyelination. Repeated infusions appear in some protocols, implying single-course durability is not assumed.
Multiple sclerosis arises from immune-mediated attack on myelin and oligodendrocytes in the central nervous system, causing demyelination and axonal loss. Stem-cell strategies target both immune dysregulation and repair: placental mesenchymal stem cells are studied for their capacity to calm autoreactive immune cells and secrete neuroprotective factors, while neurogenic cells are explored for remyelination and axonal support. Preclinical work suggests stem cells migrate toward lesions and release anti-inflammatory mediators. Trials have enrolled relapsing-remitting and progressive forms, but the mechanism of any benefit is incompletely characterised, and no approach yet reverses established disability or halts long-term progression in humans.
Am I a candidate? → · Multiple Sclerosis: full overview → · Multiple Sclerosis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם